Multi-drug resistant Bacteroides fragilis recovered from blood and severe leg wounds caused by an improvised explosive device (IED) in Afghanistan

Anaerobe

Volumn 17, Issue 4, 2011, Pages 152-155

  Sherwood, Jeffrey E ^a,f   Fraser, Susan ^a   Citron, Diane M ^b   Wexler, Hana ^c   Blakely, Garry ^d   Jobling, Kelly ^d   Patrick, Sheila ^e  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b R M ALDEN RESEARCH LABORATORY   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^f NONE   (United States)

Author keywords

Bacteroides fragilis; Linezolid; Multi drug resistance; NimE; Plasmid

Indexed keywords

CARBAPENEM; CEFOXITIN; CLINDAMYCIN; IMIPENEM; LINEZOLID; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN;

ABSENCE OF SIDE EFFECTS; ADULT; AFGHANISTAN; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; BACTEROIDES INFECTION; BLAST INJURY; BLOOD CULTURE; CASE REPORT; CERVICAL SPINE FRACTURE; DEBRIDEMENT; ESCHERICHIA COLI; FIBULA FRACTURE; FRACTURE FIXATION; HUMAN; LEG INJURY; MALE; MULTIDRUG RESISTANCE; NONHUMAN; PLASMID; PRIORITY JOURNAL; TIBIA FRACTURE; WATER CONTAMINATION; WOUND INFECTION; WOUND IRRIGATION;

BACTEROIDES FRAGILIS;

EID: 80051951299     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2011.02.007     Document Type: Article

References (18)

1. Wexler H. Bacteroides fragilis: the good, the bad, and the nitty-gritty. Clin Microbiol Rev Oct 2007, 20(4):593-621.
2. Snydman D.R., Jacobus N.V., McDermott L.A., Golan Y., Hecht D.W., Goldstein E.J.C., et al. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007). Clin Infect Dis 2010, 50(Suppl. 1):S26-S33.
3. Wareham D.W., et al. Anaerobic sepsis due to multidrug-resistant Bacteroides fragilis: microbiological cure and clinical response with linezolid therapy. Clin Infect Dis 2005, 40:e67-e68.
4. Pumbwe L., Wareham D.W., Aduse-Opoku J., et al. Genetic analysis of multidrug resistance in a clinical isolate of Bacteroides fragilis. Clin Microbiol Infect 2007, 13:183-189.
5. Edwards R., et al. Prevalence and degree of expression of the carbapenemase gene (cfiA) among clinical isolates of Bacteroides fragilis in Nottingham, UK. J Antimicrob Chemother 1999, 43:273-276.
6. Liu C.-Y., et al. Increasing Trends in antimicrobial resistance among clinically Important anaerobes and Bacteroides fragilis isolates Causing Nosocomial infections: Emerging resistance to carbapenems. Antimicrob Agents Chemother Sept 2008, 52(9):3161-3168.
7. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standards 2007, Clinical Laboratory Standards Institute, M11-A7, Clinical Laboratory Standards Institute, Wayne, PA. 7th ed.
8. Soki J., Wareham D.W., Ratkai C., et al. Prevalence, nucleotide sequence and expression studies of two proteins of a 5.6kb, class III, Bacteroides plasmid frequently found in clinical isolates from European countries. Plasmid Mar 2010, 63(2):86-97. Epub Dec 21 2009.
9. Soki J., Fodor E., Hecht D.W., et al. Molecular characterization of imipenem-resistant, cfia- positive Bacteroides fragilis isolates from the USA, Hungary, and Kuwait. J Med Microbiol 2004, 53:413-419.
10. Patrick S., Duerden B.L. Gram-negative non-spore forming obligate anaerobes. Principles and Practice of clinical Bacteriology 2006, 541-556. Wiley, London. 2nd ed. S.H. Gillespie, P. Hawkey (Eds.).
11. Sund C.J., Rocha E.R., Tzianabos A.O., Wells W.G., et al. The Bacteroides fragilis transcriptome response to oxygen and H2O2: the role of OxyR and its effect on survival and virulence. Mol Microbiol Jan 2008, 67(1):129-142.
12. Afghanistan: Post-Conflict environmental Assessment 2003, 1-180. United Nations Evironmental Programme, [Switzerland]. T. Davis (Ed.).
13. Patrick S. Bacteroides. pp. 1921-1948. Molecular medical Microbiology 2002, Academic Press, London. M. Sussman (Ed.).
14. Patel E.H., Paul L.V., Casanueva A.I., Patrick S., Abratt V.R. Overexpression of the rhamnose catabolism regulatory protein, RhaR: a novel mechanism for metronidazole resistance in Bacteroides thetaiotaomicron. J Antimicrob Chemother 2009, 64:267-273.
15. Steffens L.S., Nicholson S., Paul L.V., Nord C.E., Patrick S., Abratt V.R. Bacteroides fragilis RecA protein overexpression causes resistance to metronidazole. Res Microbiol 2010, 161:346-354.
16. Lofmark S., Fang H., Hedberg M., Edlund C. Inducible metronidazole resistance and nim genes in clinical Bacteroides fragilis group isolates. Antimicrob Agents Chemother 2005, 49:1253-1256.
17. Behra-Miellet J., Calvet L., Dubreuil L. Activity of linezolid against anaerobic bacteria. Int J Antimicrob Agents Jul 2003, 22(1):28-34.
18. Livermore D.M. Linezolid in vitro: mechanism and antimicrobial spectrum. J Antimicrob Chemother 2003, 51(Suppl. S2):ii9-ii16.